Skip to content

Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men

Robert M. Grant, Javier R. Lama, Peter L. Anderson, Vanessa McMahan, Albert Liu, Lorena Silva Vargas, Pedro Goicochea, Martín Casapía, Juan V. Guanira, Maria Esther Ramirez-Cardich, Orlando Montoya, Telmo Fernández, Valdilea Gonçalves Veloso, Susan Buchbinder, Suwat Chariyalertsak, Mauro Schechter, Linda‐Gail Bekker, Kenneth Hugh Mayer, Esper Georges Kallas, K. Rivet Amico, Kathleen M. Mulligan, Lane R. Bushman, Robert J. Hance, Carmela Ganoza, Patricia A. Defechereux, Brian S. Postle, Furong Wang, J. Jeff McConnell, Jia‐Hua Zheng, Jeanny Lee, James F. Rooney, Howard S. Jaffe, Ana I. Martínez, David Burns, David V. Glidden

New England Journal of Medicine · 2010 · 5,215 citationsOpen access

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A., Vargas, L. S., Goicochea, P., Casapía, M., Guanira, J. V., Ramirez-Cardich, M. E., Montoya, O., Fernández, T., Veloso, V. G., Buchbinder, S., Chariyalertsak, S., Schechter, M., Bekker, L., Mayer, K. H., Kallas, E. G., … Glidden, D. V. (2010). Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New England Journal of Medicine, 363(27), 2587–2599. https://doi.org/10.1056/nejmoa1011205

In text: (Grant et al., 2010)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

BACKGROUND: Antiretroviral chemoprophylaxis before exposure is a promising approach for the prevention of human immunodeficiency virus (HIV) acquisition. METHODS: We randomly assigned 2499 HIV-seronegative men or transgender women who have sex with men to receive a combination of two oral antiretroviral drugs, emtricitabine and tenofovir disoproxil fumarate (FTC-TDF), or placebo once daily. All subjects received HIV testing, risk-reduction counseling, condoms, and management of sexually transmitted infections. RESULTS: The study subjects were followed for 3324 person-years (median, 1.2 years; maximum, 2.8 years). Of these subjects, 10 were found to have been infected with HIV at enrollment, and 100 became infected during follow-up (36 in the FTC-TDF group and 64 in the placebo group), indicating a 44% reduction in the incidence of HIV (95% confidence interval, 15 to 63; P=0.005). In the FTC-TDF group, the study drug was detected in 22 of 43 of seronegative subjects (51%) and in 3 of 34 HIV-infected subjects (9%) (P<0.001). Nausea was reported more frequently during the first 4 weeks in the FTC-TDF group than in the placebo group (P<0.001). The two groups had similar rates of serious adverse events (P=0.57). CONCLUSIONS: Oral FTC-TDF provided protection against the acquisition of HIV infection among the subjects. Detectable blood levels strongly correlated with the prophylactic effect. (Funded by the National Institutes of Health and the Bill and Melinda Gates Foundation; ClinicalTrials.gov number, NCT00458393.).

  1. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility2009
  2. Prevention of HIV-1 Infection with Early Antiretroviral Therapy2011
  3. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents1998
  4. 1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults1993
  5. HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor1996

Metadata from OpenAlex (CC0). Citations are generated from the published record.